Hepatitis C virus‐related symptoms, but not quality of life, were improved by treatment with direct‐acting antivirals
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
AIM: Direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection have a significantly high sustained virologic response rate after a short treatment course and do not have any severe adverse effects. Patient-reported outcomes (PROs) have become increasingly important to assess the total impact of a chronic disease. We aimed to evaluate the changes in symptoms of patients with HCV infection treated with DAAs by using PROs. METHODS: A total of 107 patients with chronic HCV infection were treated with DAAs. Daclatasvir/asunaprevir or sofosbuvir/ledipasvir was used for HCV 1B infection, and sofosbuvir/ribavirin for HCV 2A/2B infection. The PROs measured at the start of treatment and 1 year after the start of treatment were cirrhosis-related symptom score (CSS), presence of restless legs syndrome (RLS), Epworth sleepiness scale (ESS), Pittsburg sleep quality index (PSQI), Kessler 6 score (K-6), and the SF-36 to measure quality of life (QOL). All patients had a sustained virologic response rate of 24. RESULTS: The CSS, PSQI, K-6, and RLS scores were improved 1 year after beginning treatment. However, QOL had not recovered. Changes in total CSS were correlated with HCV genotype, sex, hypertensive drug use, serum low-density lipoprotein, and ESS at the start of treatment and RLS 1 year after the start of treatment. The factors that contributed to worsening of CSS were HCV genotype 2B and RLS 1 year after the start of treatment. CONCLUSION: Treatment with DAAs eliminated HCV-RNA and improved most symptoms, but QOL did not recover.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Hepatitis C virus‐related symptoms, but not quality of life, were improved by treatment with direct‐acting antivirals
- Date Crossref
- 13/11/2017
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Nagasaki Medical Center pays non établi dans la noticeÉtablissement de santé
-
Nagasaki University Department of Comprehensive Community Care Systems pays non établi dans la noticeUniversité ou école supérieure
-
Department of Gastroenterology Nagasaki Harbor Medical Center Nagasaki Japan Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Innovation and Translational Research Center Nagasaki Harbor Medical Center Nagasaki Japan pays non établi dans la noticeStructure de recherche
-
Graduate School of Biomedical Sciences Department of Comprehensive Community Care Systems pays non établi dans la noticeUniversité ou école supérieure
Nagasaki Medical Center, Department of Comprehensive Community Care Systems — Nagasaki University et Department of Gastroenterology — Department of Gastroenterology Nagasaki Harbor Medical Center Nagasaki Japan, avec 2 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.